<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3182">
  <stage>Registered</stage>
  <submitdate>2/06/2011</submitdate>
  <approvaldate>2/06/2011</approvaldate>
  <nctid>NCT01366131</nctid>
  <trial_identification>
    <studytitle>Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)</studytitle>
    <scientifictitle>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GO27811</secondaryid>
    <secondaryid>MEF4984g</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-Squamous Non-Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MEGF0444A
Treatment: drugs - bevacizumab
Treatment: drugs - carboplatin
Treatment: drugs - paclitaxel
Treatment: drugs - placebo

Experimental: A - 

Experimental: B - 


Treatment: drugs: MEGF0444A
Intravenous repeating dose

Treatment: drugs: bevacizumab
Intravenous repeating dose

Treatment: drugs: carboplatin
Intravenous repeating dose

Treatment: drugs: paclitaxel
Intravenous repeating dose

Treatment: drugs: placebo
Intravenous repeating dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (defined as the time from randomization to the first occurrence of progression based on RECIST 1.1 criteria or death from any cause on study)</outcome>
      <timepoint>Up to 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response (partial response plus complete response) as determined by the Investigator using RECIST 1.1</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of objective response (defined as the first occurrence of a documented objective response until the time of progression or death from any cause on study)</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (defined as the time from randomization until death from any cause)</outcome>
      <timepoint>Up to 24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically or cytologically documented inoperable (Stage IV) or recurrent
             non-squamous non-small cell lung cancer (NSCLC). Diagnoses of non-squamous NSCLC that
             are based on sputum cytology alone are not acceptable. Mixed tumors should be
             categorized according to the predominant cell type.

          -  ECOG performance status of 0 or 1

          -  Life expectancy &gt;12 weeks

          -  Measurable disease, as defined by RECIST 1.1

          -  Adequate hematologic and end organ function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior therapy (including chemotherapy, antibody therapy, tyrosine kinase
             inhibitors,radiotherapy, immunotherapy, hormonal therapy or investigational therapy)
             before Day 1 of Cycle 1 for the treatment of Stage IV or recurrent NSCLC. Patients who
             received prior adjuvant chemotherapy or radiotherapy for NSCLC are not excluded if the
             time interval from completion of adjuvant therapy until disease progression is &gt; 12
             months.

          -  Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days prior to enrollment

          -  Malignancies other than NSCLC within 5 years prior to randomization, except for
             adequately treated carcinoma in situ of the cervix, basal or squamous cell skin
             cancer, localized prostate cancer treated surgically with curative intent, ductal
             carcinoma in situ treated surgically with curative intent

          -  Pregnant and lactating women

          -  Active infection requiring IV antibiotics

        Bevacizumab-Specific Exclusions:

          -  Histologically or cytologically documented inoperable, locally advanced, mixed
             non-small cell and small cell tumors or mixed adenosquamous carcinomas with a
             predominant squamous component

          -  Evidence of tumor invading major blood vessels on imaging

          -  Evidence of central nervous system (CNS) metastases

          -  History of stroke or transient ischemic attacks (TIAs) within 6 months prior to Day 1

          -  Significant vascular disease within 6 months prior to Day 1

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>104</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital> - St. Leonards</hospital>
    <hospital> - Herston</hospital>
    <hospital> - Woodville South</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>5011 - Woodville South</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava - Poruba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Herblain</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gauting</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Grosshansdorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szekesfehervar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Tatab√°nya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed
      to evaluate the efficacy and safety of MEGF0444A combined with paclitaxel + carboplatin +
      bevacizumab therapy in patients with histologically or cytologically documented inoperable,
      locally advanced, metastatic (Stage IV), or recurrent non-squamous NSCLC.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01366131</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ina Rhee, M.D., Ph.D.</name>
      <address>Genentech, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>